EffRx Pharmaceuticals SA, a pharmaceutical company specializing in musculoskeletal and rare diseases medications, has disclosed the signing of an exclusive licensing and distribution arrangement for Binosto® in Vietnam and the Philippines with Lupin Limited (Lupin), a prominent global pharmaceutical company.…
Ono Pharmaceutical Co., Ltd. (Osaka, Japan), led by President and CEO Gyo Sagara, has announced a significant milestone today. The company has formalized an option and collaboration agreement with Numab Therapeutics AG (Horgen, Switzerland), under the leadership of CEO David…
Today, GSK has announced the successful completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced, this acquisition includes AIO-001, a…
Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with narcolepsy type 1. Narcolepsy, a chronic and rare neurological disorder…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion cohort within the Japanese Phase I study. This study aimed…
Novartis has announced its intent to initiate a voluntary public takeover offer for the acquisition of MorphoSys AG (FSE: MOR; NASDAQ: MOR), a global biopharmaceutical company headquartered in Germany, specializing in innovative oncology medicines. The proposed acquisition, contingent upon customary…
Merck Animal Health, operating as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, N.J., USA, has officially entered into a definitive agreement to acquire Elanco Animal Health…
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…
ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a renowned Japanese multinational recognized for its innovative approaches in healthcare…
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat CER* DKK million Net sales 232,261…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have concluded investment agreement with Niremia Collective, a venture capital firm specializing in Well-being Technology-focused funds (Headquarters: California, USA; Representative: Naoko Okumoto,…
